As previously reported, Evercore ISI analyst Vijay Kumar downgraded Azenta (AZTA) to In Line from Outperform with a price target of $62, up from $60, citing the base business outlook and share loss to Twist Bioscience (TWST).
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZTA:
- Azenta downgraded to In Line from Outperform at Evercore ISI
- Azenta Soars on Q4 Beat; Instates $1.5B Stock Buyback
- Azenta approves $1.5B share repurchase program
- Azenta sees Q1 non-GAAP EPS 8c-16c, one estimate 9c
- Azenta Reports Fourth Quarter and Full Year Fiscal 2022 Results, Authorizes $1.5 Billion Share Repurchase Program